

RESEARCH ARTICLE

Open Access



# Incidence of cardiovascular events and associated risk factors in kidney transplant patients: a competing risks survival analysis

María Teresa Seoane-Pillado<sup>1</sup>, Salvador Pita-Fernández<sup>1\*</sup>, Francisco Valdés-Cañedo<sup>2</sup>, Rocio Seijo-Bestilleiro<sup>1</sup>, Sonia Pértega-Díaz<sup>1</sup>, Constantino Fernández-Rivera<sup>2</sup>, Ángel Alonso-Hernández<sup>2</sup>, Cristina González-Martín<sup>1</sup> and Vanesa Balboa-Barreiro<sup>1</sup>

## Abstract

**Background:** The high prevalence of cardiovascular risk factors among the renal transplant population accounts for increased mortality. The aim of this study is to determine the incidence of cardiovascular events and factors associated with cardiovascular events in these patients.

**Methods:** An observational ambispective follow-up study of renal transplant recipients ( $n = 2029$ ) in the health district of A Coruña (Spain) during the period 1981–2011 was completed. Competing risk survival analysis methods were applied to estimate the cumulative incidence of developing cardiovascular events over time and to identify which characteristics were associated with the risk of these events.

Post-transplant cardiovascular events are defined as the presence of myocardial infarction, invasive coronary artery therapy, cerebral vascular events, new-onset angina, congestive heart failure, rhythm disturbances, peripheral vascular disease and cardiovascular disease and death. The cause of death was identified through the medical history and death certificate using ICD9 (390–459, except: 427.5, 435, 446, 459.0).

**Results:** The mean age of patients at the time of transplantation was  $47.0 \pm 14.2$  years; 62% were male. 16.5% had suffered some cardiovascular disease prior to transplantation and 9.7% had suffered a cardiovascular event. The mean follow-up period for the patients with cardiovascular event was  $3.5 \pm 4.3$  years. Applying competing risk methodology, it was observed that the accumulated incidence of the event was 5.0% one year after transplantation, 8.1% after five years, and 11.9% after ten years. After applying multivariate models, the variables with an independent effect for predicting cardiovascular events are: male sex, age of recipient, previous cardiovascular disorders, pre-transplant smoking and post-transplant diabetes.

**Conclusions:** This study makes it possible to determine in kidney transplant patients, taking into account competitive events, the incidence of post-transplant cardiovascular events and the risk factors of these events. Modifiable risk factors are identified, owing to which, changes in said factors would have a bearing of the incidence of events.

**Keywords:** Kidney transplantation, Cardiovascular diseases, Risk factors, Survival analysis

\* Correspondence: salvador.pita.fernandez@sergas.es

<sup>1</sup>Clinical Epidemiology and Biostatistics Research Group, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complejo Hospitalario Universitario de A Coruña (CHUAC), SERGAS, Universidade da Coruña, Hotel de Pacientes 7ª Planta, C/As Xubias de Arriba, 84, 15006 A Coruña, Spain  
Full list of author information is available at the end of the article

## Background

Cardiovascular disease is one of the most common complications after renal transplantation [1]. Although some authors have documented a significant reduction in cardiovascular death after kidney transplantation [2], today cardiovascular disease is still the major known cause of death in kidney transplant patients [3].

Long-term graft failure is secondary to chronic allograft nephropathy, recurrent disease, and death with a functioning graft. Recurrent disease is becoming an important cause of late graft failure and cardiovascular illnesses and neoplasms are the two main causes of death with normal function of the graft in the long-term follow-up of kidney transplant patients [4].

Conventional cardiovascular risk factors such as hyperlipidaemia, hypertension and diabetes are common in transplant recipients, partly because of the effects of immunosuppressive drugs, and are associated with adverse outcomes [5, 6]. Determining the incidence of cardiovascular events after a kidney transplant and the associated risk factors is important to inform physicians of the need of cardiovascular disease screening and prevention as part of the transplant evaluation [7, 8]. On the other hand, an accurate estimation of a patient's risk of cardiovascular disease could allow identifying people at risk of a cardiovascular event and intervene before they develop the disease.

The study was conducted with the aim determining the incidence of cardiovascular events and the variables associated with the same, employing competing risk methodology to estimate the events of interest.

## Methods

### Study type

Ambispective observational follow-up study within a cohort of renal-transplant recipients. The protocol of this study has been already published [9].

### Research setting

The study included all the kidney transplants performed at the Nephrology Department of Complejo Hospitalario Universitario de A Coruña (Spain) during 1981–2011. This hospital is of reference at a regional level for kidney transplantation and at a national level for combined kidney-pancreas transplantation. It is a 1,382-bed public tertiary care hospital attending a population of nearly 560,000 inhabitants.

### Study population

An observational prospective follow-up study with a retrospective component during the period 1981–2011 was completed. During said period 2,313 kidney transplants were performed, corresponding to 2,029 patients.

Patients who had received transplants were identified through the hospital's transplant registry.

### Measurements

For each patient, information included donor and recipient characteristics, patient and graft survival after transplantation. Information about cardiovascular risk factors at the time of transplantation was also collected and post-transplant cardiovascular events were registered. The follow-up period for each patient starts on the day of transplantation and continues until death or last reported contact.

Post-transplant cardiovascular events are defined as the presence of myocardial infarction, invasive coronary artery therapy (coronary balloon angioplasty, stents and bypass surgery), cerebral vascular events (stroke and transient ischemic attacks), new-onset angina, congestive heart failure, rhythm disturbances (ventricular tachycardia, atrial fibrillation and the need for a pacemaker), peripheral vascular disease and cardiovascular disease, death. The cause of death was identified through the medical history and death certificate using ICD9 (390–459, except: 427.5, 435, 446, 459.0).

### Sample size justification

The sample size ( $n = 2,029$ ) makes it possible to detect as significant HR  $\geq 1.305$  with a prevalence of exposure to a risk factor of 50% and a censored data percentage of 78% (Security: 95%; Statistical power: 80%).

### Statistical analysis

A descriptive analysis of the variables recorded was performed. Competing risk survival analysis methods were applied to estimate the cumulative incidence of developing events over time from kidney transplantation. These methods allow for the fact that a patient may experience an event which is different from that of interest. These events are known as competing risk events, and may preclude the onset of the event of interest, or may modify the probability of the onset of that event. In particular, a transplanted patient may die or lose the graft without suffering a cardiovascular event. In a Kaplan-Meier estimation approach, these individuals would be treated as censored and would be eliminated from the risk set, leading to misleading results. Using competing risks, the probability of any event happening is partitioned into the probabilities for each type of event.

To determine cardiovascular event-free survival, the primary outcome was the estimation of the probability of cardiovascular disease.

The accumulated occurrence of cardiovascular disease during the follow-up period was estimated using the method proposed by Kalbfleisch and Prentice [10]. The accumulated occurrence of cardiovascular events according to different

characteristics was compared using the test proposed by Gray [11]. Finally, in order to identify which characteristics were associated with the risk of cardiovascular events, a multivariate analysis was carried out using the model proposed by Fine and Gray [12]. All of the tests were carried out bilaterally, considering values of  $p < 0.05$  as significant. The analyses were carried out using the programmes R 3.2.3 and SPSS 19.0.

## Results

The baseline characteristics of the kidney transplant recipients are given in Table 1.

During the study period, a total of 2,313 transplants were performed at the University Hospital Complex in A Coruña, corresponding to  $n = 2,029$  patients. The characteristics of the transplants performed and the prevalence of cardiovascular risk factors at the time of transplantation are shown in Table 1.

The graft continued to function at the end of follow-up in 53.3% of transplants, the graft was lost in 30.2% of cases and 16.5% of patients did not survive. Among the causes of death with a functioning graft, the most frequent were infections (28.4%), cardiovascular disease (24.2%) and post-transplant cancer (10.5%). A total of 9.7% of transplantation patients suffered a cardiovascular event during follow-up.


If we analyse the incidence of cardiovascular events and factors associated with the same, it can be observed that the rate of incidence per 1,000 individuals-year of follow-up for cardiovascular events is 22.9 (95% CI: 19.8–26.3), with the mean time elapsed from transplantation to the onset of the cardiovascular event being  $3.5 \pm 4.3$  years. It can be seen that the rate is higher in men than in women (26.8 vs. 16.6 per 1,000 individuals/year;  $p = 0.003$ ) and increases in proportion to the recipient's age. In patients aged 45 or under, the incidence rate is  $12.0 \times 1000$  individuals/year. Between 46 and 55 years of age, the incidence rate is  $26.7 \times 1000$  individuals/year. In the 56–65 year old age group, it is  $3.0 \times 1000$  individuals/year, and for patients over 65 years of age, it is  $69.1 \times 1000$  individuals/year.

Applying competing risk methodology, it can be observed that the accumulated incidence for cardiovascular events one year after transplantation, after two years, after five years and after ten years, is 5.0, 5.6, 8.1 and 11.9%, respectively (Fig. 1).

The bivariate analysis (Table 2) shows that patients experiencing a cardiovascular event are generally older. At the end of follow-up, 11.2% of the males had suffered a cardiovascular event as opposed to 7.2% of women. The highest percentage of events was in pre-transplantation smokers and post transplantation smokers, in patients with previous cardiovascular disease (cerebral vascular events (stroke and transient ischemic attacks), ischemic heart disease, congestive heart failure, peripheral vascular

**Table 1** Baseline characteristics and cardiovascular risk factors of the kidney transplant recipients

| Baseline characteristics                    | Mean      | SD   | Median    |
|---|-----------|------|-----------|
| Age of recipient (years)                    | 46.97     | 14.2 | 49.00     |
| Age of donor (years)                        | 42.07     | 18.7 | 44.00     |
| Time in renal replacement therapy (months)  | 31.1      | 35.0 | 20.00     |
|   | n         | %    | 95% CI    |
| Gender of recipient                         |           |      |           |
| Men   | 1266/2029 | 62.4 | 60.3–64.5 |
| Women                                       | 763/2029  | 37.6 | 35.5–39.7 |
| Gender of donor                             |           |      |           |
| Men   | 1329/1982 | 67.1 | 65.0–69.1 |
| Women                                       | 653/1982  | 32.9 | 30.9–35.0 |
| Live donor                                  | 83/1939   | 4.3  | 3.4–5.2   |
| Pre-transplant substitutive renal therapy   |           |      |           |
| Haemodialysis                               | 1462/1951 | 74.9 | 73.0–76.9 |
| Peritoneal dialysis                         | 489/1951  | 25.1 | 23.1–27.0 |
| Prior transplant                            |           |      |           |
| First transplant                            | 1745/2029 | 86.0 | 84.5–87.5 |
| Re-transplant                               | 284/2029  | 14.0 | 12.5–15.5 |
| DR compatibilities                          |           |      |           |
| 0   | 184/1942  | 9.5  | 8.1–10.8  |
| 1   | 1340/1942 | 69.0 | 66.9–71.1 |
| 2   | 418/1942  | 21.5 | 19.7–23.4 |
| ABO Compatibilities                         |           |      |           |
| 0   | 377/1955  | 19.3 | 17.5–21.1 |
| 1   | 791/1955  | 40.5 | 38.3–42.7 |
| 2   | 660/1955  | 33.8 | 31.6–35.9 |
| 3   | 101/1955  | 5.2  | 4.2–6.2   |
| 4   | 26/1955   | 1.3  | 0.8–1.9   |
| Type of transplant                          |           |      |           |
| Kidney                                      | 1927/2008 | 95.5 | 94.6–96.4 |
| Kidney + liver                              | 19/2008   | 0.94 | 0.5–1.4   |
| Kidney + pancreas                           | 55/2008   | 2.73 | 2.0–3.5   |
| Kidney + heart                              | 12/2008   | 0.59 | 0.2–0.9   |
| Kidney + heart + liver                      | 1/2008    | 0.05 | 0.001–0.3 |
| Kidney + lung                               | 4/2008    | 0.20 | 0.05–0.5  |
| Cardiovascular Risk Factors                 | n         | %    | 95% CI    |
| Previous cardiovascular disease             | 328/1983  | 16.5 | 14.9–18.2 |
| Obesity (BMI $\geq 30\text{kg/m}^2$ )       | 191/1598  | 12.0 | 10.3–13.6 |
| Pre-transplant hypertension                 | 1698/1982 | 85.7 | 84.1–87.2 |
| Pre-transplant left ventricular hypertrophy | 850/1856  | 45.8 | 43.5–48.1 |
| Pre-transplant diabetes mellitus            | 176/1999  | 8.8  | 7.5–10.1  |
| Pre-transplant smoker                       | 477/1007  | 47.4 | 44.2–50.5 |



disease and arrhythmias), in those diagnosed with high post-transplantation blood pressure, in those with left ventricular hypertrophy and post-transplant diabetes. Patients with cardiovascular events had higher levels of glycemic control than patients without cardiovascular events.

After modelling the incidence of cardiovascular events employing specific competing risk techniques, with the patient’s death or graft loss being those events competing with the presence of the event of interest, adjusting for different factors, it can be seen that those variables with a bearing on the presence of cardiovascular events subsequent to kidney transplantation are male gender, age of the recipient, prior cardiovascular disease, pre-transplant smoking and diabetes (Table 3).

**Discussion**

In this study, data were collected on 2,029 kidney transplant patients, with a mean age of 47.0 ± 14.2 years, and 62.4% of which were men. A cardiovascular event was suffered by 9.7% of these patients. The accumulated incidence of a cardiovascular event in the presence of

**Table 2** Comparison of recipient kidney transplant according to presence or absence of cardiovascular event

|   | No Cardiovascular Event   |                             | Cardiovascular Event       |             | Univariate Survival Models |       |
|---|---------------------------|-----------------------------|----------------------------|-------------|----------------------------|-------|
|   | Mean ± sd                 | Mean ± sd                   | Sig.                       | HR          | 95% CI (HR)                |       |
| Receptor age  | 46.5 ± 14.4               | 51.5 ± 11.5                 | <0.001                     | 1.038       | 1.026                      | 1.049 |
| Weight (Kg)   | 67.9 ± 22.5               | 69.8 ± 13.5                 | 0.015                      | 1.004       | 1.001                      | 1.007 |
| BMI (kg/m <sup>2</sup> )                              | 25.3 ± 8.3                | 25.9 ± 3.9                  | 0.050                      | 1.009       | 1.000                      | 1.019 |
| Proteinuria (g/24h)                                   | 0.5 ± 0.9                 | 0.6 ± 1.0                   | 0.086                      | 1.112       | 0.985                      | 1.256 |
| Hemoglobin (g/dL)                                     | 10.0 ± 2.9                | 9.0 ± 2.7                   | 0.685                      | 0.958       | 0.777                      | 1.180 |
| Hematocrit (%)  | 32.7 ± 8.9                | 31.8 ± 7.1                  | 0.417                      | 1.006       | 0.992                      | 1.020 |
| Glomerular filtration rate estimated (Cockroft-Gault) | 44.5 ± 24.4               | 43.8 ± 22.9                 | 0.182                      | 0.995       | 0.988                      | 1.002 |
| Glomerular filtration rate estimated (MDRD)           | 40.5 ± 25.5               | 39.9 ± 24.5                 | 0.120                      | 0.995       | 0.989                      | 1.001 |
| Glomerular filtration rate estimated (CKD-EPI)        | 50.1 ± 31.5               | 44.8 ± 28.2                 | 0.062                      | 0.995       | 0.990                      | 1.001 |
| Systolic blood pressure (mmHg)                        | 141.6 ± 21.3              | 145.3 ± 22.3                | 0.230                      | 1.004       | 0.998                      | 1.010 |
| Diastolic blood pressure (mmHg)                       | 81.9 ± 12.4               | 81.3 ± 11.6                 | 0.195                      | 0.992       | 0.981                      | 1.004 |
| Cholesterol (mg/dL)                                   | 147.8 ± 40.4              | 152.3 ± 42.6                | 0.717                      | 1.001       | 0.997                      | 1.004 |
| Cholesterol HDL (mg/dL)                               | 40.6 ± 17.8               | 36.9 ± 15.4                 | 0.580                      | 0.993       | 0.969                      | 1.017 |
| Cholesterol LDL (mg/dL)                               | 121.2 ± 35.6              | 111.6 ± 41.9                | 0.349                      | 0.992       | 0.976                      | 1.009 |
| Triglycerides (mg/dL)                                 | 140.7 ± 73.5              | 150.8 ± 77.0                | 0.266                      | 1.001       | 0.999                      | 1.003 |
| Glucose (mg/dL)                                       | 120.1 ± 59.7              | 124.7 ± 49.7                | 0.190                      | 1.001       | 0.999                      | 1.002 |
|   | Event in exposed subjects | Event in unexposed subjects | Univariate Survival Models |             |                            |       |
|   | n (%)                     | n (%)                       | Sig.                       | Exp(β) = HR | 95% CI (HR)                |       |
| Gender (ref:woman)                                    | 142 (11.2)                | 55 (7.2)                    | 0.002                      | 1.615       | 1.182                      | 2.205 |
| Previous cardiovascular illness                       | 65 (19.8)                 | 131 (7.9)                   | <0.001                     | 2.972       | 2.206                      | 4.004 |
| Pre-transplantation smokers                           | 65 (13.1)                 | 33 (6.5)                    | <0.001                     | 2.819       | 1.842                      | 4.316 |
| Post-transplantation smokers                          | 22 (15.0)                 | 69 (8.2)                    | <0.001                     | 2.323       | 1.434                      | 3.763 |
| Pre-transplantation hypertension                      | 165 (9.7)                 | 30 (10.6)                   | 0.472                      | 1.154       | 0.781                      | 1.707 |
| Post-transplantation hypertension                     | 193 (10.3)                | 4 (3.6)                     | 0.037                      | 2.872       | 1.067                      | 7.731 |
| Diabetes  | 67 (14.0)                 | 129 (8.5)                   | <0.001                     | 1.820       | 1.360                      | 2.430 |
| Left ventricular hypertrophy                          | 109 (13.9)                | 75 (7.0)                    | <0.001                     | 2.150       | 1.602                      | 2.886 |

**Table 3** Multivariate competing risk regression model of a cardiovascular event after kidney transplantation

|                                   | $\beta$ | se ( $\beta$ ) | $p$   | HR   | 95% CI |      |
|-----------------------------------|---------|----------------|-------|------|--------|------|
| Gender (ref: woman)               | 0.589   | 0.288          | 0.041 | 1.80 | 1.02   | 3.17 |
| Receptor age                      | 0.021   | 0.007          | 0.005 | 1.02 | 1.01   | 1.04 |
| Previous cardiovascular illness   | 0.655   | 0.221          | 0.003 | 1.92 | 1.25   | 2.97 |
| Pre-transplant smoking            | 0.558   | 0.242          | 0.021 | 1.75 | 1.09   | 2.81 |
| Post-transplant diabetes mellitus | 0.585   | 0.212          | 0.006 | 1.79 | 1.18   | 2.72 |

competing risks was 5.0% in the first year, 6.6% after three years, 8.1% after five years and 11.9% after ten years. These results are consistent with those published in multicentre studies, including data from transplanted patients from North America, Europe and countries on the Pacific coast, in which the accumulated incidence of coronary events and the accumulated incidence of myocardial infarct after kidney transplant is estimated [13, 14].

Various epidemiological studies have identified the factors associated with an increase in the probability of falling ill or dying owing to cardiovascular disease after kidney transplantation [15–17]. They also test whether the risk factors identified for the general population also increased the risks in kidney transplant patients and to what extent. These studies would suggest that the cardiovascular risk factors for the general population (e.g. high blood pressure, hyperlipidaemia and smoking) are predictive of events in the transplanted population. Diabetes doubles the risk of events in men and triples the risk in women with respect to that estimated for the general population; moreover, it is shown that the episodes of acute rejection during the first year after transplantation are associated with a greater risk [15, 16]. In the study by Weiner, D. E. [17] the factors associated significantly with an increased risk of cardiovascular disease in transplanted patients were old-age, prior cardiovascular disease, diabetes, smoking, systolic and diastolic blood pressure and low BMI and glomerular filtration rates estimated with the CKD-EPI formula lower than 45ml/min/1.73m<sup>2</sup>. Other traditional risk factors in the general population, such as gender, LDL Cholesterol and triglycerides, were not significant.

For cerebrovascular disease (ischaemic cerebrovascular accident, haemorrhagic cerebrovascular accidents and transient ischaemic attacks) after kidney transplantation, the risk factors were age, pre- and post-transplant smoking, diabetes, high blood pressure, obesity and coronary comorbidity [5].

The results of our study are consistent with those in the literature. After performing survival models, we have identified the following as predictors of cardiovascular events: male gender, age of recipient, the presence of

prior cardiovascular disease, pre-transplant smoking and post-transplant diabetes. The presence of these factors along with the higher age of the recipient increases the risk of cardiovascular events.

Here we should stress the importance of complications related with immunosuppressant treatment, of which diabetes mellitus is perhaps most important, owing to the vascular problems it gives rise to [18–21]. We believe that the prevention of new-onset diabetes is a key strategy for reducing post-transplant cardiovascular mortality. The individualisation of immunosuppression guidelines (selection of calcineurin inhibitor and the steroid dosage) may be an effective measure for controlling the incidence of post-transplant diabetes and modifying the cardiovascular risk in this patient group.

Among the limitations of the study, we could point out that with a view to minimising the selection bias, information was collected on all transplants performed during the study period. There were no significant differences in information losses among patients presenting the event of interest or not. In order to minimise any information biases, mean values of the baseline measurements closest in time were calculated. Left ventricular hypertrophy was diagnosed by ECG. As opposed to previous studies—based on the retrospective analysis of records, which only contain information prior to transplantation and from short-term follow-up—this study provides long-term information on clinical and analytic parameters and with regard to the treatment of kidney transplant recipients. Although the information was gathered from hospital medical records, which could result in an information bias, the characteristics of these patients mean that they are subject to much more exhaustive follow-up than is habitual, not only during the period immediately after transplantation, but throughout the entire follow-up period. Thus, during the first year after kidney transplantation, patients were seen every 3 months, every 6 months in the 10 years following a transplant, and once a year after the first 10 years of follow-up. The study included a large cohort of patients with a long period of post-transplantation follow-up, which has enabled us to obtain valid results on the long-term results of kidney transplantation. Among the confounding biases, it should be noted that there are risks factors which were not included, information in relation with the heart failure according to the functional state was not available and also the level of HbA1c expressing glycaemic control in diabetics was not included. Treatments, which modify the variables studied, were not included. In order to control the confusion, we have employed multivariate regression techniques. The population at risk changes over time in a population of survivors due to the occurrence of competing events. It is possible that the presence of competing events has an impact on the effect estimates over time.

The majority of the studies published in the literature employ the habitual survival analysis techniques, assuming that there is only one event of interest, and that censoring is not informative; i.e., that if we monitored censored patients, they would have the same rate for the event as non-censored patients [22]. In practice these assumptions are not always correct; generally speaking, an individual may experience more than one type of event, or experience a type of event which hinders or modifies the probability of observing the event of interest. Competing risk survival analysis enables us to determine the factors associated with the incidence of a specific event. Fine & Gray [12] modified Cox's proportional risk model to take into account competing risks.

It is becoming progressively easier to secure comprehensive data sets with full follow-up; consequently, the need to apply mathematical methodologies focused on the precise type of analysis is also increasing. Owing to the foregoing, our principal aim must be to apply specific techniques, such as competing risks, from the design phase of the study up to the interpretation of the results obtained.

## Conclusions

This study has made it possible to determine, in a cohort of kidney transplant recipients, and taking into account competing events, the post-transplant incidence of said events and the risk factors associated with the same. Modifiable risk factors have been identified, owing to which, said factors would have a bearing of the incidence of cardiovascular events in this patient group.

## Abbreviations

BMI: Body mass index; CKD-EPI: Chronic kidney disease epidemiology collaboration; HR: Hazard ratio

## Acknowledgements

This study has also received the backing of the Health Promotion and Preventive Activities – Primary Health Care Network, which is supported by grants from the Spanish Ministry of Health ISCIII-RETICI G03/170 and RD06/0018. The authors would like to thank the nephrologists and urologists who are participating in the follow-up of the patients.

## Funding

This research has received a grant from the Spanish Ministry of Science and Innovation, Carlos III Institute, Health Research Fund, no. PI070986, and from the Regional Ministry of Health (Xunta de Galicia, Spain), no. PS09/26.

## Availability of data and materials

Not applicable.

## Authors' contributions

SPF, SPD, FVC and RSB participated in the design and coordination of the study. SPD, TSP and VBB are the biostatisticians of the study. TSP, SPF, SPD, FVC, RSB, CFR, AAH, CGM and, VBB reviewed the study protocol and made suggestions that improved the design. All of these individuals are involved in the management of the study. All of the authors read, revised and approved the final manuscript.

## Competing interests

The authors declare that they have no competing interests.

## Consent for publication

Not applicable.

## Ethics approval and consent to participate

The study was carried out according to the principles laid down in the Declaration of Helsinki and ensuring compliance with Spanish Law 29/2009, which "Regulates the use of and access to electronic medical records. Confidentiality was maintained in accordance with the current Spanish Data Protection Law (15/1999). The study has received written approval from the region's Ethics Committee for Clinical Research (code 2007/019 CEIC Galicia).

## Author details

<sup>1</sup>Clinical Epidemiology and Biostatistics Research Group, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complejo Hospitalario Universitario de A Coruña (CHUAC), SERGAS, Universidade da Coruña, Hotel de Pacientes 7ª Planta, C/As Xubias de Arriba, 84, 15006 A Coruña, Spain. <sup>2</sup>Department of Nephrology, A Coruña Hospital, As Xubias 84, A Coruña 15006, Spain.

Received: 15 November 2016 Accepted: 28 February 2017

Published online: 07 March 2017

## References

- Foley R, Parfrey P, Sarnak M. Epidemiology of cardiovascular disease in chronic renal disease. *J Am Soc Nephrol*. 1998;9 Suppl 12:S16–23.
- Pilmore H, Dent H, Chang S, et al. Reduction in cardiovascular death after kidney transplantation. *Transplantation*. 2010;89:851–7.
- U.S. Renal Data System. USRDS 2014 annual data report: volume one: chronic kidney disease in the United States and volume two: end-stage renal disease in the United States. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2014.
- Hernández D, Sánchez-Fructuoso A, González-Posada J, et al. A novel risk score for mortality in renal transplant recipients beyond the first posttransplant year. *Transplantation*. 2009;88:803–9.
- Lentine K, Rey L, Kolli S, et al. Variations in the risk for cerebrovascular events after kidney transplant compared with experience on the waiting list and after graft failure. *Clin J Am Soc Nephrol*. 2008;3:1090–101.
- Jardine A, Gaston R, Fellstrom B, et al. Prevention of cardiovascular disease in adult recipients of kidney transplants. *Lancet*. 2011;378:1419–27.
- Svensson M, Jardine A, Fellström B, Holdaas H. Prevention of cardiovascular disease after renal transplantation. *Curr Opin Organ Transplant*. 2012;17(4): 393–400.
- Special Issue. KDIGO clinical practice guideline for the care of kidney transplant recipients. *Am J Transplant*. 2009;9:S1–155.
- Pita-Fernández S, Pértiga-Díaz S, Valdés-Cañedo F, Seijo-Bestilleiro R, Seoane-Pillado T, Fernández-Rivera C, Alonso-Hernández A, Lorenzo-Aguiar D, López-Calvino B, López-Muñiz A. Incidence of cardiovascular events after kidney transplantation and cardiovascular risk scores: study protocol. *BMC Cardiovasc Disord*. 2011;11:2.
- Kalbfleisch J, Prentice R. *The statistical analysis of failure time data*. New York: Wiley; 1980.
- Gray R. A class of K-sample tests for comparing the cumulative incidence of a competing risk. *Ann Stat*. 1988;16:1141–54.
- Fine J, Gray R. A proportional hazards model for the subdistribution of a competing risk. *J Am Stat Assoc*. 1999;94:496.
- Israni A, Snyder J, Skeans M, et al. Predicting coronary heart disease after kidney transplantation: patient outcomes in renal transplantation (PORT) study. *Am J Transplant*. 2010;10:338–53.
- Lentine K. Incidence and predictors of myocardial infarction after kidney transplantation. *J Am Soc Nephrol*. 2005;16:496–506.
- Kasiske B. Epidemiology of cardiovascular disease after renal transplantation. *Transplantation*. 2001;72(Supplement):S5–8.
- Jardine A, Fellström B, Logan J, et al. Cardiovascular risk and renal transplantation: post hoc analyses of the assessment of lescol in renal transplantation (ALERT) study. *Am J Kidney Dis*. 2005;46:529–36.
- Weiner D, Carpenter M, Levey A, et al. Kidney function and risk of cardiovascular disease and mortality in kidney transplant recipients: the FAVORIT trial. *Am J Transplant*. 2012;12:2437–45.
- Kasiske B, Snyder J, Gilbertson D, et al. Diabetes mellitus after kidney transplantation in the United States. *Am J Transplant*. 2003;3:178–85.

19. Martínez-Castelao A, Hernández M, Pascual J, et al. Detection and treatment of post kidney transplant hyperglycemia: a Spanish multicenter cross-sectional study. *Transplant Proc.* 2005;37:3813–6.
20. Davidson J, Wilkinson A, Dantal J, et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. *Transplantation.* 2003;75:SS3–24.
21. Porrini E, Moreno J, Osuna A, et al. Prediabetes in patients receiving tacrolimus in the first year after kidney transplantation: a prospective and multicenter study. *Transplantation.* 2008;85:1133–8.
22. Lee E, Go O. Survival analysis in public health research. *Annu Rev Public Health.* 1997;18:105–34.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

